Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential PCV13 then PPSV23 vs PPSV23 alone in immunocompromised adults (CPI study)
jRCT1090220246Recruiting
- Sponsor
- National Hospital Organization Mie National Hospital
- Start
- Apr 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in Pneumococcal pneumonia (PP) and invasive pneumococcal disease (IPD) comparing Sequential PCV13 then PPSV23 with Single PPSV23 after placebo (2 arms). Primary endpoint: Incidence of pneumococcal pneumonia. Started Apr 2016; status: recruiting.
02
Drugs
Prevnar 1323-valent pneumococcal polysaccharide vaccine
03
Conditions
Pneumococcal pneumonia (PP)invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on jRCT1090220246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220246.